4-(chloro-6-isopropoxy-1,2,3-triazin-2yl)morpholine | 1197161-06-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 英文名称: 4-(chloro-6-isopropoxy-1,2,3-triazin-2yl)morpholine
• 英文别名: 4-(chloro-6-isopropoxyl-1,2,3-triazin-2-yl)morpholine；4-(4-Chloro-6-isopropoxy-1,3,5-triazin-2-yl)morpholine；4-(4-chloro-6-propan-2-yloxy-1,3,5-triazin-2-yl)morpholine
• CAS: 1197161-06-0
• 化学式: C₁₀H₁₅ClN₄O₂
• 分子量: 258.708
• InChiKey: CNUAMWZXZGOYFS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  60.4
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-(chloro-6-isopropoxy-1,2,3-triazin-2yl)morpholine 在 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 水 为溶剂， 反应 2.58h， 生成 N-[2-(dimethylamino)ethyl]-4-({[4-(4-isopropoxy-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)benzamide
  参考文献：
  名称：

  Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors

  摘要：

  We recently described several highly potent, triazine (1) and triazolopyrimidine (2) scaffold-based, dual PI3K/mTOR-inhibitors (e.g., 1, PKI-587) that were efficacious in both in vitro and in vivo models. In order to further optimize these compounds we devised a novel series, the 2-oxatriazines, which also exhibited excellent potency and good metabolic stability. Some 2-oxatriazines showed promising in vivo biomarker suppression and induced apoptosis in the MDA-MB-361 breast cancer xenograft model. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.06.063
• 作为产物：
  描述：

  2,4-二氯-6-吗啉基-1,3,5-三嗪 、 异丙醇 在 正丁基锂 作用下， 以 四氢呋喃 为溶剂， 反应 24.5h， 生成 4-(chloro-6-isopropoxy-1,2,3-triazin-2yl)morpholine
  参考文献：
  名称：

  TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS

  摘要：

  式I化合物，其中：R1为，R2、R4和R6-9如本文所定义，以及其药学上可接受的盐和酯。这些化合物抑制PI3激酶和mTOR，并可用于治疗由PI3激酶和mTOR介导的疾病，例如多种癌症。本发明还公开了制备和使用这些化合物的方法。此外，还公开了含有本发明化合物的各种组合物。

  公开号：

  US20170119778A1

文献信息

• TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS
  申请人：WYETH LLC

  公开号：US20170119778A1

  公开（公告）日：2017-05-04

  Compounds of formula I wherein: R 1 is and R 2 , R 4 , and R 6-9 are defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this invention are disclosed. Various compositions containing the compounds of this invention are also disclosed.

  式I化合物，其中：R1为，R2、R4和R6-9如本文所定义，以及其药学上可接受的盐和酯。这些化合物抑制PI3激酶和mTOR，并可用于治疗由PI3激酶和mTOR介导的疾病，例如多种癌症。本发明还公开了制备和使用这些化合物的方法。此外，还公开了含有本发明化合物的各种组合物。
• Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors
  作者：Christoph M. Dehnhardt、Aranapakam M. Venkatesan、Zecheng Chen、Efren Delos-Santos、Semiramis Ayral-Kaloustian、Natasja Brooijmans、Ker Yu、Irwin Hollander、Larry Feldberg、Judy Lucas、Robert Mallon

  DOI：10.1016/j.bmcl.2011.06.063

  日期：2011.8

  We recently described several highly potent, triazine (1) and triazolopyrimidine (2) scaffold-based, dual PI3K/mTOR-inhibitors (e.g., 1, PKI-587) that were efficacious in both in vitro and in vivo models. In order to further optimize these compounds we devised a novel series, the 2-oxatriazines, which also exhibited excellent potency and good metabolic stability. Some 2-oxatriazines showed promising in vivo biomarker suppression and induced apoptosis in the MDA-MB-361 breast cancer xenograft model. (C) 2011 Elsevier Ltd. All rights reserved.